Abstract Sjogren’s disease (SjD) is an autoimmune disease that is characterized not only by the sicca symptoms it causes but also by its systemic nature, which is capable of several and not yet fully understood extraglandular manifestations. To gain a clearer understanding of these manifestations as well as a better practical approach, a panel of experts from the Brazilian Society of Rheumatology conducted a systematic review and meta-analysis on the identification of epidemiologic and clinical features of the extraglandular manifestations present in ESSDAI (EULAR Sjogren´s syndrome disease activity index), followed by a voting panel with recommendations for clinical practice. This publication is complementary to others already published and covers cutaneous and hematological manifestations, with prevalence data generated by a meta-analysis of 13 clinical or laboratory manifestations and 6 clinical management recommendations. Sjogrens Sjogren s SjD (SjD nature approach metaanalysis meta analysis EULAR index, index , index) practice 1

ABSTRACT BACKGROUND: Osteoporosis compromises bone strength and increases the risk of fractures. Zoledronate prevents loss of bone mass and reduces the risk of fractures. OBJECTIVES: To determine the efficacy and safety of zoledronate in postmenopausal women with osteopenia and osteoporosis. DESIGN AND SETTINGS A systematic review and meta-analysis was conducted within the evidence-based health program at the Universidade Federal de São Paulo. METHODS: An electronic search of the CENTRAL, MEDLINE, Embase, and LILACS databases was performed until February 2022. Randomized controlled trials comparing zoledronate with placebo or other bisphosphonates were included. Standard methodological procedures were performed according to the Cochrane Handbook and the certainty of evidence for the Grading of Recommendations Assessment, Development, and Evaluation Working Group. Two authors assessed the risk of bias and extracted data on fractures, adverse events, bone turnover markers (BTM), and bone mineral density (BMD). RESULTS: Twelve trials from 6,652 records were included: nine compared zoledronate with placebo, two trials compared zoledronate with alendronate, and one trial compared zoledronate with ibandronate. Zoledronate reduced the incidence of fractures in osteoporotic [three years: morphometric vertebral fractures (relative risk, RR = 0.30 (95% confidence interval, CI: 0.24–0.38))] and osteopenic women [six years: morphometric vertebral fractures (RR = 0.39 (95%CI: 0.25–0.61))], increased incidence of post-dose symptoms [RR = 2.56 (95%CI: 1.80–3.65)], but not serious adverse events [RR = 0.97 (95%CI: 0.91–1.04)]. Zoledronate reduced BTM and increased BMD in osteoporotic and osteopenic women. CONCLUSION: This review supports the efficacy and safety of zoledronate in postmenopausal women with osteopenia for six years and osteoporosis for three years. PROSPERO REGISTRATION NUMBER: CRD42022309708, https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=309708. BACKGROUND OBJECTIVES metaanalysis meta analysis evidencebased based Paulo METHODS CENTRAL MEDLINE Embase 2022 included Assessment Development Group BTM, , (BTM) BMD. . (BMD) RESULTS 6652 6 652 6,65 alendronate ibandronate relative 030 0 30 0.3 95% 95 (95 interval CI 0.24–0.38 024038 24 38 0.24–0.38)) 039 39 95%CI 95CI (95%CI 0.25–0.61, 025061 0.25–0.61 25 61 0.25–0.61))] postdose post dose 256 2 56 2.5 1.80–3.65, 180365 1.80–3.65 1 80 3 65 1.80–3.65)] 097 97 0.9 0.91–1.04. 091104 0.91–1.04 91 04 0.91–1.04)] CONCLUSION NUMBER CRD42022309708 CRD https//www.crd.york.ac.uk/prospero/display_record.phpRecordID=309708. httpswwwcrdyorkacukprosperodisplayrecordphpRecordID309708 httpswwwcrdyorkacukprosperodisplayrecordphpRecordID https //www.crd.york.ac.uk/prospero/display_record.php RecordID=309708. www crd york ac uk prospero display record php RecordID 309708 https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=309708 202 (BTM (BMD 665 6,6 03 0. 9 (9 0.24–0.3 02403 0.24–0.38) 02506 0.25–0.6 0.25–0.61)) 5 2. 18036 1.80–3.6 8 1.80–3.65) 09 09110 0.91–1.0 0.91–1.04) CRD4202230970 phpRecordID https//www.crd.york.ac.uk/prospero/display_record.phpRecordID=309708 httpswwwcrdyorkacukprosperodisplayrecordphpRecordID30970 wwwcrdyorkacukprosperodisplayrecordphp RecordID309708 RecordID=309708 30970 https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=30970 20 66 6, ( 0.24–0. 0240 0250 0.25–0. 0.25–0.61) 1803 1.80–3. 0911 0.91–1. CRD420223097 https//www.crd.york.ac.uk/prospero/display_record.phpRecordID=30970 httpswwwcrdyorkacukprosperodisplayrecordphpRecordID3097 RecordID30970 RecordID=30970 3097 https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=3097 0.24–0 024 025 0.25–0 180 1.80–3 091 0.91–1 CRD42022309 https//www.crd.york.ac.uk/prospero/display_record.phpRecordID=3097 httpswwwcrdyorkacukprosperodisplayrecordphpRecordID309 RecordID3097 RecordID=3097 309 https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=309 0.24– 02 0.25– 18 1.80– 0.91– CRD4202230 https//www.crd.york.ac.uk/prospero/display_record.phpRecordID=309 httpswwwcrdyorkacukprosperodisplayrecordphpRecordID30 RecordID309 RecordID=309 https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=30 0.24 0.25 1.80 0.91 CRD420223 https//www.crd.york.ac.uk/prospero/display_record.phpRecordID=30 httpswwwcrdyorkacukprosperodisplayrecordphpRecordID3 RecordID30 RecordID=30 https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=3 0.2 1.8 CRD42022 https//www.crd.york.ac.uk/prospero/display_record.phpRecordID=3 RecordID3 RecordID=3 https://www.crd.york.ac.uk/prospero/display_record.php?RecordID= 1. CRD4202 https//www.crd.york.ac.uk/prospero/display_record.phpRecordID= RecordID= https://www.crd.york.ac.uk/prospero/display_record.php?RecordID CRD420 https//www.crd.york.ac.uk/prospero/display_record.phpRecordID CRD42 CRD4

Abstract Sjogren's syndrome (SS) is an autoimmune disease characterized by lymphocytic infiltration of the exocrine glands and other organs, associated with sicca syndrome but also with systemic involvement with varying degrees of severity. Despite their importance, some systemic manifestations, mainly liver, gastrointestinal, and pancreatic are not routinely evaluated. To address these manifestations, the Sjögren's Syndrome Committee of the Brazilian Society of Rheumatology conducted a broad systematic review of the literature on studies investigating prevalence and diagnosis of these symptoms in Sjogren´s patients and made recommendations based on the findings. Agreement between the experts was achieved using the Delphi method. This is the second part of this guideline, providing 6 recommendations for liver, gastrointestinal, and pancreatic care of SS patients.

Abstract Sjogren’s Syndrome (SS) is an autoimmune disease characterized by lymphocytic infiltration of the exocrine glands and other organs, associated with sicca syndrome but also with systemic involvement with varying degrees of severity. Despite their importance, these systemic manifestations are not routinely evaluated and there is no homogenous approach to their diagnosis or evaluation. To close this gap, a panel of experts from the Brazilian Society of Rheumatology conducted a systematic review and meta-analysis on the identification of epidemiologic and clinical features of these manifestations and made recommendations based on the findings. Agreement between the experts was achieved using the Delphi method. The first part of this guideline summarizes the most important topics, and 11 recommendations are provided for the articular, pulmonary, and renal care of SS patients.

Abstract Sjogren’s syndrome (SS) is an autoimmune disease characterized by lymphocytic infiltration of the exocrine glands and other organs. Women with SS often experience gynecological symptoms due to the disease and need extra care regarding their sexual activity, reproductive health and during pregnancy, conditions that are not properly conducted in the clinical practice. To cover this gap, a panel of experts from the Brazilian Society of Rheumatology conducted a systematic review and meta-analysis on the identification of symptoms, diagnosis, monitoring, prognosis, and treatment of these manifestations. A Focus Group meeting was held and included experts in the field and methodologists, based on a previously developed script, with themes related to the objective of the study. The most important topics were summarized and 11 recommendations were provided.

ABSTRACT BACKGROUND: Fatigue is a frequent symptom in patients with primary Sjögren’s syndrome (pSS) and can be a cause of or be associated with sleep disorders. OBJECTIVE: To assess the sleep quality of pSS patients and its relationship with fatigue and disease activity. DESIGN AND SETTING: Analytical observational study conducted at an exercise psychobiology laboratory. METHODS: Sleep quality was evaluated using the Pittsburg sleep quality index (PSQI) and actigraphy. Fatigue was evaluated through the Profile of Fatigue and Discomfort - Sicca Symptoms Inventory (PROFAD-SSI-SF) and a visual analogue scale for fatigue (VAS-fatigue). Disease activity was evaluated using a visual analogue scale for pain (VAS-pain), EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) and Disease Activity Index (ESSDAI). We summarized the data through descriptive statistics. RESULTS: A total of 50 female patients with pSS, of average age 56.4 years, were included in the study; 80% presented low disease activity. The total PSQI score showed that 74% had poor sleep. The actigraphy showed mean sleep latency of 26.2 minutes and mean nightly awakening of 48.2 minutes (duration of wakings after sleep onset, WASO). There were correlations between PSQI and VAS-pain, VAS-fatigue, PROFAD-SSI and ESSPRI. Actigraphy showed a correlation between the duration of WASO and ESSDAI. CONCLUSION: The present study provides important information regarding correlations between sleep disorders and disease activity. There is a need for proper control over disease activity and for development of strategies to help patients to sleep better in order to diminish their fatigue.

Abstract Background: In Brazil, we are facing an alarming epidemic scenario of Yellow fever (YF), which is reaching the most populous areas of the country in unvaccinated people. Vaccination is the only effective tool to prevent YF. In special situations, such as patients with chronic immune-mediated inflammatory diseases (CIMID), undergoing immunosuppressive therapy, as a higher risk of severe adverse events may occur, assessment of the risk-benefit ratio of the yellow fever vaccine (YFV) should be performed on an individual level. Main body of the abstract: Faced with the scarcity of specific orientation on YFV for this special group of patients, the Brazilian Rheumatology Society (BRS) endorsed a project aiming the development of individualized YFV recommendations for patients with CIMID, guided by questions addressed by both medical professionals and patients, followed an internationally validated methodology (GIN-McMaster Guideline Development). Firstly, a systematic review was carried out and an expert panel formed to take part of the decision process, comprising BRS clinical practitioners, as well as individuals from the Brazilian Dermatology Society (BDS), Brazilian Inflammatory Bowel Diseases Study Group (GEDIIB), and specialists on infectious diseases and vaccination (from Tropical Medicine, Infectious Diseases and Immunizations National Societies); in addition, two representatives of patient groups were included as members of the panel. When the quality of the evidence was low or there was a lack of evidence to determine the recommendations, the decisions were based on the expert opinion panel and a Delphi approach was performed. A recommendation was accepted upon achieving ≥80% agreement among the panel, including the patient representatives. As a result, eight recommendations were developed regarding the safety of YFV in patients with CIMID, considering the immunosuppression degree conferred by the treatment used. It was not possible to establish recommendations on the effectiveness of YFV in these patients as there is no consistent evidence to support these recommendations. Conclusion: This paper approaches a real need, assessed by clinicians and patient care groups, to address specific questions on the management of YFV in patients with CIMID living or traveling to YF endemic areas, involving specialists from many areas together with patients, and might have global applicability, contributing to and supporting vaccination practices. We recommended a shared decision-making approach on taking or not the YFV.

Abstract Background: Primary Sjögren's syndrome (pSS) is a systemic immune-mediated disease whose main characteristic is exocrine gland inflammation and, subsequent reduction in tear and saliva production. A delayed diagnosis is common due to the nonspecific clinical manifestations of disease. The aim of the present study was to develop recommendations for the diagnosis of glandular manifestations of pSS based on evidence and expert opinion. Main body of the abstract: We conducted a systematic literature review to retrieve the best evidence available on the accuracy of diagnostic tests for pSS. We also held two in-person meetings with experts (rheumatologists, pathologists, ophthalmologists and dentists) to establish their level of agreement using the Delphi method. Ultimately, we generated 18 recommendations that aim to facilitate the diagnosis of the glandular manifestations of pSS. Conclusion: The diagnosis of glandular manifestations of pSS is complex and multidisciplinary. It requires specific knowledge in the field of ophthalmology, immunology, pathology and imaging, making it compulsory for the rheumatologist to work with professionals from these different areas in order to improve accuracy and early diagnosis. Glandular dysfunction tests, ANA, RF, Anti-Ro, protein electrophoresis, urinalysis, blood count, C-Reactive protein, complement, testing for syphilis and viruses (HCV, HIV) and SGUS should be investigated when dryness or systemic manifestation are present. Minor salivary gland biopsy is recommended for all anti-Ro negative or incomplete criteria cases.

Resumo A febre chikungunya tem se tornado um importante problema de saúde pública nos países onde ocorrem as epidemias, visto que metade dos casos evolui com artrite crônica, persistente e incapacitante. Os dados na literatura sobre terapêuticas específicas nas diversas fases da artropatia ocasionada pela infecção pelo vírus chikungunya (CHIKV) são limitados, não existem estudos randomizados de qualidade que avaliem a eficácia das diferentes terapias. Há algumas poucas publicações sobre o tratamento das manifestações musculoesqueléticas da febre chikungunya, porém com importantes limitações metodológicas. Os dados atualmente disponíveis não permitem conclusões favoráveis ou contrárias a terapêuticas específicas, bem como uma adequada avaliação quanto à superioridade entre as diferentes medicações empregadas. O objetivo deste trabalho foi elaborar recomendações para o tratamento da febre chikungunya no Brasil. Foi feita uma revisão da literatura com seleção de artigos baseados em evidência, nas bases de dados Medline, SciELO, PubMed e Embase e de resumos de anais de congressos, além da opinião dos especialistas para dar apoio às decisões tomadas para definir as recomendações. Para a definição do grau de concordância foi feita uma metodologia Delphi, em duas reuniões presenciais e várias rodadas de votação on line. Este artigo refere-se à parte 2 das Recomendações da Sociedade Brasileira de Reumatologia para Diagnóstico e Tratamento da Febre Chikungunya, que trata especificamente do tratamento.

Abstract Chikungunya fever has become an important public health problem in countries where epidemics occur because half of the cases progress to chronic, persistent and debilitating arthritis. Literature data on specific therapies at the various phases of arthropathy caused by chikungunya virus (CHIKV) infection are limited, lacking quality randomized trials assessing the efficacies of different therapies. There are a few studies on the treatment of musculoskeletal manifestations of chikungunya fever, but these studies have important methodological limitations. The data currently available preclude conclusions favorable or contrary to specific therapies, or an adequate comparison between the different drugs used. The objective of this study was to develop recommendations for the treatment of chikungunya fever in Brazil. A literature review was performed via evidence-based selection of articles in the databases Medline, SciELO, PubMed and Embase and conference proceedings abstracts, in addition to expert opinions to support decision-making in defining recommendations. The Delphi method was used to define the degrees of agreement in 2 face-to-face meetings and several online voting rounds. This study is part 2 of the Recommendations of the Brazilian Society of Rheumatology (Sociedade Brasileira de Reumatologia - SBR) for the Diagnosis and Treatment of chikungunya fever and specifically addresses treatment.

Resumo A febre chikungunya tem se tornado um importante problema de saúde pública nos países onde ocorrem as epidemias. Até 2013, as Américas haviam registrado apenas casos importados quando, em outubro desse mesmo ano, foram notificados os primeiros casos na Ilha de Saint Martin, no Caribe. No Brasil, os primeiros relatos autóctones foram confirmados em setembro de 2014 e até a semana epidemiológica 37 de 2016 já haviam sido registrados 236.287 casos prováveis de infecção pelo chikungunya vírus (CHIKV), 116.523 confirmados sorologicamente. As mudanças ambientais causadas pelo homem, o crescimento urbano desordenado e o número cada vez maior de viagens internacionais têm sido apontados como os fatores responsáveis pela reemergência de epidemias em grande escala. Caracterizada clinicamente por febre e dor articular na fase aguda, em cerca de metade dos casos existe evolução para a fase crônica (além de três meses), com dor persistente e incapacitante. O objetivo deste trabalho foi elaborar recomendações para diagnóstico e tratamento da febre chikungunya no Brasil. Para isso, foi feita revisão da literatura nas bases de dados Medline, SciELO e PubMed, para dar apoio às decisões tomadas para definir as recomendações. Para a definição do grau de concordância foi feita uma metodologia Delphi, em duas reuniões presenciais e várias rodadas de votação on line. Foram geradas 25 recomendações, divididas em três grupos temáticos: (1) diagnóstico clínico, laboratorial e por imagem; (2) situações especiais e (3) tratamento. Na primeira parte estão os dois primeiros temas e o tratamento na segunda.

Abstract Chikungunya fever has become a relevant public health problem in countries where epidemics occur. Until 2013, only imported cases occurred in the Americas, but in October of that year, the first cases were reported in Saint Marin island in the Caribbean. The first autochthonous cases were confirmed in Brazil in September 2014; until epidemiological week 37 of 2016, 236,287 probable cases of infection with Chikungunya virus had been registered, 116,523 of which had serological confirmation. Environmental changes caused by humans, disorderly urban growth and an ever-increasing number of international travelers were described as the factors responsible for the emergence of large-scale epidemics. Clinically characterized by fever and joint pain in the acute stage, approximately half of patients progress to the chronic stage (beyond 3 months), which is accompanied by persistent and disabling pain. The aim of the present study was to formulate recommendations for the diagnosis and treatment of Chikungunya fever in Brazil. A literature review was performed in the MEDLINE, SciELO and PubMed databases to ground the decisions for recommendations. The degree of concordance among experts was established through the Delphi method, involving 2 in-person meetings and several online voting rounds. In total, 25 recommendations were formulated and divided into 3 thematic groups: (1) clinical, laboratory and imaging diagnosis; (2) special situations; and (3) treatment. The first 2 themes are presented in part 1, and treatment is presented in part 2.

Poliangiite granulomatosa é uma doença sistêmica que afeta qualquer órgão, com predileção pelo trato respiratório superior, pulmões e rins. Este artigo tem como objetivo relatar um caso atípico de uma paciente com esclerite nodular como manifestação inicial da poliangiite granulomatosa (Wegener), mimetizando um quadro de tuberculose. A paciente apresentou hiperemia ocular e baixa acuidade visual progressiva por 1,5 anos, seguido por dor ocular por dois meses. A paciente possuía nódulos subpleurais com densidade de partes moles, linfonodomegalia em janela aorto-pulmonar e espessamento pleural bilateral discreto, negativo para bacilos álcool-ácido resistentes (BAAR). O diagnóstico histológico revelou uma vasculite granulomatosa sugestiva de vasculite não infecciosa (poliangiite granulomatosa). Foi iniciada pulsoterapia com ciclofosfamida.

Granulomatous polyangiitis is a systemic disease that may affect any organ, with a predilection for the upper respiratory tract, lungs and kidneys. This article aims to report a case of a patient with atypical nodular scleritis as the initial manifestation of granulomatous polyangiitis (Wegener), mimicking a case of tuberculosis. The patient presented ocular hyperemia and lower progressive visual acuity for 1.5 years, followed by eye pain for two months. The patient had subpleural nodules with soft tissue density, increased pulmonary lymph nodes and discrete bilateral pleural thickening, with negative alcohol-resistant acid bacilli (BAAR). The histological diagnosis revealed a granulomatous vasculitis suggestive of non-infectious vasculitis (granulomatous polyangiitis). Cyclophosphamide pulse therapy was initiated.

OBJETIVO: O objetivo do estudo foi realizar a tradução e a adaptação e estudar as propriedades das medidas: reprodutibilidade, validade e consistência interna do índice Manchester de incapacidade associada ao pé doloroso no idoso (MFPDI) para a língua portuguesa. MÉTODOS: O MFPDI foi traduzido e adaptado culturalmente para uma população de idosos, residentes na cidade de São Paulo. Foram avaliados 85 pacientes ambulatoriais com idade de 60 anos ou mais, de ambos os sexos, que apresentavam dor nos pés de 30 mm ou mais na escala analógica visual de dor (EVA). Os pacientes foram submetidos ao MFPDI por três vezes, visto que na primeira vez cada paciente foi avaliado pelos entrevistadores 1 e 2 no mesmo dia, e no período máximo de 15 dias cada paciente foi, novamente, avaliado pelo entrevistador 1 para realizar a fase de reprodutibilidade. Para verificar a validade, foram colhidas medidas sociodemográficas, morfológicas e valores da escala analógica visual. E para a consistência interna foi aplicado o alfa de Cronbach, a fim de verificar a confiabilidade das respostas nas três entrevistas. RESULTADOS: Ao utilizar o processo metodológico, foi possível observar que a população ambulatorial entrevistada apresentou incapacidade funcional associada ao pé doloroso. A consistência interna foi alta (alfa de Cronbach = 0,80) entre as entrevistas. A validade foi obtida comparando-se o MFPDI com a EVA, sendo possível observar que, apesar de baixa, a correlação foi significante (p < 0,001). CONLUSÃO: Com o processo de tradução e adaptação cultural do MFPDI demonstraram-se as propriedades de medida de reprodutibilidade, validade e consistência interna.

OBJECTIVE: This work aimed to translate into Portuguese, make adaptations, and study the reproducibility, validation and internal consistency of the parameters of the "Manchester Foot-Pain Disability Index". METHODS: The MFPDI was translated and culturally adapted in a population of eighty-five (85) elderly people, living in the city of São Paulo, seen at the outpatient clinics of the .Instituto de Geriatria e Gerontologia of the Escola Paulista de Medicina. The patients had at least 60 years-old, of either sex, displaying foot pain of at least 30 mm on a visual analog scale (VAS). Patients were evaluated by 3 times by the MFPDI, in such a way that on the first time each patient was evaluated by the interviewers 1 and 2 at the same day; to assess reproducibility, within the next 15 days each patient was evaluated again by the interviewer 1. Validation was verified by checking for social and demographic data, as well as morphological and VAS values. Internal consistency was checked by means of the Cronbach alpha, assessing reproducibility of the answers in the three interviews. RESULTS: The MFPDI index demonstrated that this population presented functional inability associated to foot pain. The internal consistency between interviews was high (Alpha of Cronbach = 0.80). Though presenting a weak correlation, there was a significant validity comparing MFPDI and the VAS (p < 0.001). CONCLUSION: The translation and cultural adaptation of the MFPDI provide a reproducible, consistent and valuable tool to evaluate foot pain.

OBJETIVO: Avaliar a ocorrência de incontinência urinária (IU) em atletas corredoras de longa distância e associá-la a presença ou não de distúrbios alimentares. MÉTODOS: Um total de 37 corredoras de longa distância completaram os questionários ¨International Consultation on Incontinence Questionnaire-Short Form¨ (ICIQ-SF) e o ¨Eating Attitudes Test¨ (EAT-26). O teste do absorvente de uma hora foi realizado para quantificar a perda de urina. A análise estatística das variáveis contínuas foi feita pelo teste t pareado, ou teste de Mann-Whitney. RESULTADOS: 23 atletas (62,2%) tinham queixa de perda de urina. A média dos escores do ICIQ-SF neste grupo foi de 4,03 ± 5,06. Houve diferença estatisticamente significante entre o valor do teste do absorvente (p=0,02) e o resultado do questionário EAT-26 (p=0,03) no grupo de atletas incontinentes. CONCLUSÃO: Encontramos IU em atletas corredoras de longa distância e houve correlação com distúrbios alimentar. Técnicos devem estar atentos para a ocorrência de eventuais distúrbios e encaminhar tais atletas para uma equipe multidisciplinar.

BACKGROUND: To determine the prevalence of urinary incontinence in female long-distance runners and to compare it with the presence or not of eating disorders. Methods - A total of 37 women have completed the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) and the short version of the Eating Attitudes Test (EAT-26). A one-hour pad test was performed to determine urine loss. Mean values of continuous variables were compared using an independent sample t-test or the Mann-Whitney U test. RESULTS: 23 athletes (62.2%) reported urine loss. The mean of the ICIQ-SF was 4.03 ± 5.06. There was a significant relation between the 1-hour pad test (p=0.02) and eating disorders (p=0.03). CONCLUSIONS: There was urinary incontinence in female long-distance runners and a correlation with eating disorders. Coaches should improve their knowledge about this problem and establish cooperation with a multidisciplinary team.

Apresentamos o caso de uma paciente de 64 anos, com diagnóstico de artrite reumatóide, apresentando nódulos episclerais bilaterais, sem inflamação articular ativa. A biópsia das lesões revelou presença de granulomas com células epitelióides e fibroblastos em orientação radial à zona central de degeneração necrobiótica do colágeno da episclera e esclera superficial e infiltrados de linfócitos e plasmócitos em todos os níveis da substância própria da conjuntiva. Na literatura reumatológica o desenvolvimento de nódulos reumatóides na ausência de doença articular ativa é chamado de "nodulosis rheumatoidis".

A 64-year-old woman with a diagnosis of rheumatoid arthritis developed painless bilateral episcleral rheumatoid nodules without any flareup of her associated disease. Biopsy of the lesions disclosed a lymphocytic and plasmacytic infiltration within the conjunctiva, overlying palisading granulomas with multinucleated giant cells, and central necrobiotic degeneration of the collagen of the episclera and superficial sclera. The rheumatologic designation for the development of groups of nodules in inactive rheumatoid arthritis is rheumatoid nodulosis.

A microangiopatia livedóide é uma síndrome de hialinização segmentar crônica dos vasos da derme, de causa desconhecida, que afeta principalmente os membros inferiores. Histopatologicamente, tanto as lesões iniciais quanto as tardias são caracterizadas por infiltrado com escassas células inflamatórias, mas com importante angiogênese capilar e microtrombos, aglomerados nodulares de pequenos capilares misturados com hemácias e depósitos de hemossiderina na derme. A ausência de infiltrado perivascular suficiente ou leucocitoclasia argumenta contra vasculite, favorecendo mais um processo trombótico. A microangiopatia livedóide acomete principalmente mulheres jovens e de meia idade. Pode ser idiopática, ou estar associada a alterações na coagulação, incluindo mutação no fator V de Leiden, deficiência da proteína C, aumento na homocisteína plasmática, anormalidades na fibrinólise, ativação plaquetária e síndrome do anticorpo antifosfolípide (SAF). Nós apresentamos um caso de uma paciente com microangiopatia livedóide, associada à presença de SAF com múltiplas úlceras em membros inferiores, que só apresentou melhora clínica após a anticoagulação plena com warfarina e posterior associação com danazol. A microangiopatia livedóide pode representar uma manifestação clínica inicial de um grupo de doenças que causam vasculopatia oclusiva. Logo, todo paciente deve ser investigado para presença de anticorpo antifosfolípide ou de outra causa de trombofilia.

Livedoid microangiopathy is a chronic segmental hyalinizing syndrome of dermal blood vessels, of unknown origin, that affects mainly the lower limbs. Histopathologically, both initial as well as late lesion are characterized by few inflammatory cells infiltrate, with prevalent capillary angiogenesis and microthrombi, agglomerate of small capillaries, and dermal deposits of hemosiderin. The absence of a substantial perivascular infiltrate or leukocytoclasia argues against vasculitis, favouring a thrombotic process. Livedoid microangiopathy attacks mainly young and middle-aged women; can be idiopathic, or associated with coagulation alterations including the factor V Leiden mutation, protein C deficiency, increased plasmatic homocysteine, fibrinolysis abnormalities, platelet activation and antiphospholipid antibody syndrome (APS). We describe a case of a patient with livedoid microangiopathy associated with the presence of APS with multiple ulcers in the lower limbs who showed a clinical improvement only after total anticoagulation with warfarin and association with danazol. Livedoid vasculitis can represent an initial clinical manifestation of a group of diseases which cause occlusive vasculopathy; so, every patient should be investigated for the presence of antiphospholipid antibody or of another cause of thrombophilia.